COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,536 Articles (22,881 medRxiv, 8,655 bioRxiv)

Most recent first Previous |  Page 848: Articles 8471-8480  | Next

Antibody escape and cryptic cross-domain stabilization in the SARS CoV-2 Omicron spike protein
Javanmardi, K., Segall-Shapiro, T. H., Chou, C.-W., Boutz, D. R., Olsen, R. J., Xie, X., Xia, H., Shi, P.-Y., Johnson, C. D., Annapareddy, A., Weaver, S., Musser, J. M., Ellington, A. D., Finkelstein, I. J., Gollihar, J. D.
10.1101/2022.04.18.488614 — Posted: 2022-04-18
Ocular tropism of SARS-CoV-2 with retinal inflammation through neuronal invasion in animal models
Jeong, G. U., Kwon, H.-J., Moon, H. W., Yoon, G. Y., Shin, H. J., Chae, J. S., Kim, S.-J., Lee, I.-C., Kim, K.-D., Ahn, D.-G., Mahalingam, S., Kwon, Y.-C.
10.1101/2022.04.17.488607 — Posted: 2022-04-18
The SARS-CoV-2 Omicron BA.1 spike G446S potentiates HLA-A*24:02-restricted T cell immunity
Motozono, C., Toyoda, M., Tan, T. S., Hamana, H., Aritsu, Y., Miyashita, Y., Oshiumi, H., Nakamura, K., Okada, S., Udaka, K., Kitamatsu, M., Kishi, H., Ueno, T.
10.1101/2022.04.17.488095 — Posted: 2022-04-18
Persistent post-COVID-19 smell loss is associated with inflammatory infiltration and altered olfactory epithelial gene expression
Finlay, J. B., Brann, D. H., Hachem, R. A., Jang, D. W., Oliva, A. D., Ko, T., Gupta, R., Wellford, S. A., Moseman, E. A., Jang, S. S., Yan, C. H., Matsunami, H., Tsukahara, T., Datta, S. R., Goldstein, B. J.
10.1101/2022.04.17.488474 — Posted: 2022-04-18
In Silico transcriptional analysis of asymptomatic and severe COVID-19 patients reveals the susceptibility of severe patients to other comorbidities and non-viral pathological conditions
Sen, P., Kaur, H.
10.1101/2022.04.16.488556 — Posted: 2022-04-18
Benchmarking the Widely Used Structure-based Binding Affinity Predictors on the Spike-ACE2 Deep Mutational Interaction Set
Samiloglu, E., Kosaca, M., Oktayoglu, M., Yukruk, C., Erguven, M., Arslan, N., Karakulah, G., Barlas, A. B., Savas, B., Ozden, B., Karaca, E.
10.1101/2022.04.18.488633 — Posted: 2022-04-18
Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease
Bansal, D., Abdulmajeed, J., Yassin, E., Al-Shamali, M. H. M. A., Albayat, S. S. A., Himatt, S. M., Cyprian, F. S., Chivese, T., Mundodan, J. M. A., Khogali, H., Baaboura, R., Kandy, M. C., Kaleeckal, A. H., Latif, A. N., Al-Kuwari, M. G., Al-Romaihi, H. E., Al-Khal, A. A., Bertollini, R., Al-Thani, M. H., Farag, E., Doi, S. A. R.
10.1101/2022.04.12.22273745 — Posted: 2022-04-18
Permissive Omicron breakthrough infections in individuals with binding or neutralizing antibodies to ancestral SARS-CoV-2
Williams, E., Colson, J. D., Valiathan, R., Carreno Quiroz, J. M., Krammer, F., Hoffer, M. E., Pallikkuth, S., Pahwa, S., Andrews, D.
10.1101/2022.04.17.22273938 — Posted: 2022-04-18
Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patients
Haggenburg, S., Hofsink, Q., Lissenberg-Witte, B. I., Broers, A. E. C., van Doesum, J. A., van Binnendijk, R. S., den Hartog, G., Bhoekhan, M. S., Haverkate, N. J. E., Burger, J. A., Bouhuijs, J. H., Smits, G. P., Wouters, D., van Leeuwen, E. M. M., Bontkes, H. J., Kootstra, N. A., Zweegman, S., Kater, A. P., Heemskerk, M. H. M., Groen, K., van Meerten, T., Mutsaers, P. G. N. J., Beaumont, T., van Gils, M. J., Goorhuis, A., Rutten, C. E., Hazenberg, M. D., Nijhof, I. S.
10.1101/2022.04.08.22273602 — Posted: 2022-04-18
Household transmission of SARS-CoV-2 from adult index cases living with and without HIV in South Africa, 2020-2021: a case-ascertained, prospective observational household transmission study
Kleynhans, J., Walaza, S., Martinson, N. A., Neti, M., von Gottberg, A., Bhiman, J. N., Toi, D., Amoako, D. G., Buys, A., Ndlangisa, K., Wolter, N., Genade, L., Maloma, L., Chewparsad, J., Lebina, L., de Gouveia, L., Kotane, R., Tempia, S., Cohen, C.
10.1101/2022.04.08.22273160 — Posted: 2022-04-18

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).